- Samsung Biologics reported Q1 2026 revenue of KRW 1,257 billion and operating profit of KRW 580.8 billion, driven by full utilization of Plants 1–4.
- The company expanded its global footprint with a U.S. facility acquisition and reported cumulative contract value exceeding USD 21.4 billion.
Samsung Biologics reported financial results for the first quarter of fiscal year 2026, with revenue of KRW 1,257 billion and operating profit of KRW 580.8 billion. The CDMO attributed its performance to full utilization across its first four manufacturing plants and continued execution of client projects.
The company recorded year-over-year growth compared to Q1 2025, when revenue stood at KRW 999.5 billion and operating profit at KRW 430.2 billion. EBITDA reached KRW 675.3 billion in Q1 2026. Samsung Biologics also reported cumulative contract value exceeding USD 21.4 billion, reflecting ongoing demand for its contract manufacturing services from global clients.
Operationally, the company completed the first commercial-scale engineering run at its antibody-drug conjugate facility. It also continued the ramp-up of Plant 5 at its Bio Campus, while maintaining operations across Plants 1 through 4. In March 2026, Samsung Biologics acquired a manufacturing facility in Rockville, Maryland, for USD 353 million, marking its first manufacturing presence in the United States.
“In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients.”
John Rim, President and CEO of Samsung Biologics
The company also announced partnerships with the Coalition for Epidemic Preparedness Innovations and Eli Lilly and Company, alongside continued expansion of its contract development capabilities, including cell bank production and vector construction services. Samsung Biologics reported more than 440 cumulative regulatory approvals and outlined ongoing investments to support global manufacturing capacity, supply chain resilience, and long-term growth.
